Abstract
Objective: Sepsis is a serious condition resulting from infection associated with high mortality. A high-throughput analysis of circulating blood proteins may provide mechanistic insight and potent therapeutic targets for the prevention of sepsis. Patients and Methods: We used multivariable Cox regression analysis to examine the association of 4,955 plasma proteins measured by SomaScan with the risk of incident sepsis, defined by hospital discharge with a primary diagnosis code for sepsis, among 11,065 participants of the Atherosclerosis Risk in Communities (ARIC) Study (visit 3 in 1993-95; mean age, 60.1 years, 54.4% female, 21.0% Black). Proteins (false discovery rate [FDR] of P <0.05) discovered at visit 3 were replicated using data at visit 5 (n=4,869 in 2011-13: mean age, 75.5 years) and in the Cardiovascular Health Study (CHS) (n=3,512 in 1992-93; mean age, 74.5 years). Canonical pathways were identified by enrichment analyses. Results: We identified 669 proteins associated with the risk of sepsis in the ARIC visit 3 cohort. Of those, 175 proteins were significantly associated with sepsis in the visit 5 cohort. Of the 175 proteins, 90 proteins were replicated in an external replication cohort of CHS. The top 20 proteins ranked by P value were relevant to acute inflammatory signaling in innate immunity (e.g., GDF15, EGFR, CNTN1, HDGF, NBL1, TNFRSF1A, TFRSF1B, IL15RA, SLAMF1). Pathway analyses implicated activation of pro-inflammatory pathways (e.g., cytokine storm signaling) as well as inhibition of anti-inflammatory pathways (e.g., Liver X Receptor/Retinoid X Receptor [LXR/RXR] Activation), which also play relevant roles in lipid metabolism. Conclusions: In this large-scale proteomics analysis, levels of acute inflammatory proteins measured during routine visits were associated with the subsequent incidence of sepsis. An increased risk of sepsis associated with the inhibition of anti-inflammatory pathways, such as LXR/RXR Activation warrants further mechanistic investigation.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The Atherosclerosis Risk in Communities Study has been funded in whole or in part with Federal funds from the National Heart, Lung, and Blood Institute, National Institutes of Health, Department of Health and Human Services, under Contract nos. (75N92022D00001, 75N92022D00002, 75N92022D00003, 75N92022D00004, 75N92022D00005). SomaLogic Inc. conducted the SomaScan assays in exchange for use of ARIC data. This work was supported in part by NIH/NHLBI grant R01 HL134320. The authors thank the staff and participants of the ARIC study for their important contributions. This Cardiovascular Health Study research was supported by NHLBI contracts HHSN268201200036C, HHSN268200800007C, HHSN268201800001C, N01HC55222, N01HC85079, N01HC85080, N01HC85081, N01HC85082, N01HC85083, N01HC85086, 75N92021D00006; and NHLBI grants U01HL080295, R01HL087652, R01HL105756, R01HL103612, R01HL120393, U01HL130114, HL144483 with additional contribution from the National Institute of Neurological Disorders and Stroke (NINDS). Additional support was provided through R01AG023629 from the National Institute on Aging (NIA). A full list of principal CHS investigators and institutions can be found at CHS-NHLBI.org.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
For both the Atherosclerosis Risk in Communities (ARIC) Study and the Cardiovascular Health Study (CHS), written informed consent was obtained from all participants, and the institutional review board at each study site approved the study.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos